Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014, Article ID 827827, 9 pages
http://dx.doi.org/10.1155/2014/827827
Research Article

Preferential Autoimmune Response in Prostate Cancer to Cyclin B1 in a Panel of Tumor-Associated Antigens

1Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA
2Center for Health Disparities and Molecular Medicine, Department of Basic Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92354, USA

Received 14 February 2014; Accepted 28 March 2014; Published 17 April 2014

Academic Editor: Stuart Mannering

Copyright © 2014 Liping Dai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, “Cancer statistics, 2014,” CA: A Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9–29, 2014. View at Publisher · View at Google Scholar
  2. G. Chornokur, K. Dalton, M. E. Borysova, and N. B. Kumar, “Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer,” Prostate, vol. 71, no. 9, pp. 985–997, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Culp and M. Porter, “The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men,” British Journal of Urology International, vol. 104, no. 10, pp. 1457–1461, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. A. Caire, L. Sun, T. J. Polascik, D. M. Albala, and J. W. Moul, “Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans,” British Journal of Urology International, vol. 106, no. 8, pp. 1157–1160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. G. Robinson, E. A. Hodges, and J. Davison, “Prostate-specific antigen screening: a critical review of current research and guidelines,” Journal of the American Association of Nurse Practitioners, 2014. View at Publisher · View at Google Scholar
  6. A. S. Obort, M. B. Ajadi, and O. Akinloye, “Prostate-specific antigen: any successor in sight?” Review in Urology, vol. 15, no. 3, pp. 97–107, 2013. View at Google Scholar
  7. K. S. Anderson and J. LaBaer, “The sentinel within: exploiting the immune system for cancer biomarkers,” Journal of Proteome Research, vol. 4, no. 4, pp. 1123–1133, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Zaenker and M. R. Ziman, “Serologic autoantibodies as diagnostic cancer biomarkers—a review,” Cancer Epidemiology, Biomarkers & Prevention, vol. 22, no. 12, pp. 2161–2181, 2013. View at Publisher · View at Google Scholar
  9. E. Niméus-Malmström, A. Koliadi, C. Ahlin et al., “Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort,” International Journal of Cancer, vol. 127, no. 4, pp. 961–967, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Murakami, M. Furihata, Y. Ohtsuki, and S. Ogoshi, “Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma,” Virchows Archiv, vol. 434, no. 2, pp. 153–158, 1999. View at Publisher · View at Google Scholar · View at Scopus
  11. J.-C. Soria, S. J. Jang, F. R. Khuri et al., “Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication,” Cancer Research, vol. 60, no. 15, pp. 4000–4004, 2000. View at Google Scholar · View at Scopus
  12. M. D. Begnami, J. H. Fregnani, S. Nonogaki, and F. A. Soares, “Evaluation of cell cycle protein expression in gastric cancer: cyclin B1 expression and its prognostic implication,” Human Pathology, vol. 41, no. 8, pp. 1120–1127, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. D. F. Calvisi, M. M. Simile, S. Ladu et al., “Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53,” Hepatology, vol. 53, no. 4, pp. 1226–1236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Covini, E. K. L. Chan, M. Nishioka, S. A. Morshed, S. I. Reed, and E. M. Tan, “Immune response to cyclin B1 in hepatocellular carcinoma,” Hepatology, vol. 25, no. 1, pp. 75–80, 1997. View at Google Scholar · View at Scopus
  15. Y. Yu, Y. Zhang, W. Guan et al., “Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation,” Molecular Cancer Research, 2014. View at Publisher · View at Google Scholar
  16. J. P. Pandey, A. M. Namboodiri, and E. Kistner-Griffin, “A genetic variant of FcγRIIIa is strongly associatedwith humoral immunity to cyclin B1 in African American patients with prostate cancer,” Immunogenetics, vol. 65, no. 2, pp. 91–96, 2013. View at Publisher · View at Google Scholar
  17. C. Stephan, K. Jung, M. Lein, and E. P. Diamandis, “PSA and other tissue kallikreins for prostate cancer detection,” European Journal of Cancer, vol. 43, no. 13, pp. 1918–1926, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. J.-Y. Zhang, R. Megliorino, X.-X. Peng, E. M. Tan, Y. Chen, and E. K. L. Chan, “Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma,” Journal of Hepatology, vol. 46, no. 1, pp. 107–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. F.-D. Shi, J.-Y. Zhang, D. Liu et al., “Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens,” Prostate, vol. 63, no. 3, pp. 252–258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Imai, E. K. L. Chan, K. Kiyosawa, X.-D. Fu, and E. M. Tan, “Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma,” The Journal of Clinical Investigation, vol. 92, no. 5, pp. 2419–2426, 1993. View at Google Scholar · View at Scopus
  21. J.-Y. Zhang, C. A. Casiano, X.-X. Peng, J. A. Koziol, E. K. L. Chan, and E. M. Tan, “Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens,” Cancer Epidemiology, Biomarkers & Prevention, vol. 12, no. 2, pp. 136–143, 2003. View at Google Scholar · View at Scopus
  22. E. M. Tan, “Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology,” Advances in Immunology, vol. 44, pp. 93–151, 1989. View at Google Scholar · View at Scopus
  23. J. Nielsen, J. Christiansen, J. Lykke-Andersen, A. H. Johnsen, U. M. Wewer, and F. C. Nielsen, “A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development,” Molecular and Cellular Biology, vol. 19, no. 2, pp. 1262–1270, 1999. View at Google Scholar · View at Scopus
  24. M. R. Junttila, P. Puustinen, M. Niemelä et al., “CIP2A inhibits PP2A in human malignancies,” Cell, vol. 130, no. 1, pp. 51–62, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. A. A. Sablina, W. Chen, J. D. Arroyo et al., “The tumor suppressor PP2A Aβ regulates the RalA GTPase,” Cell, vol. 129, no. 5, pp. 969–982, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Westermarck, “Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc, and c-Jun,” Methods in Molecular Biology, vol. 647, pp. 31–36, 2010. View at Google Scholar · View at Scopus
  27. M. E. Johnson and E. W. Howerth, “Survivin: a bifunctional inhibitor of apoptosis protein,” Veterinary Pathology, vol. 41, no. 6, pp. 599–607, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Aitken, “14-3-3 proteins: a historic overview,” Seminars in Cancer Biology, vol. 16, no. 3, pp. 162–172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Rayburn, R. Zhang, J. He, and H. Wang, “MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy,” Current Cancer Drug Targets, vol. 5, no. 1, pp. 27–41, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. J.-P. Kruse and W. Gu, “Modes of p53 regulation,” Cell, vol. 137, no. 4, pp. 609–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. C. J. Sherr, “The INK4a/ARF network in tumour suppression,” Nature Reviews Molecular Cell Biology, vol. 2, no. 10, pp. 731–737, 2001. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. Li and S. R. Hann, “The Myc-nucleophosmin-ARF network: a complex web unveiled,” Cell Cycle, vol. 8, no. 17, pp. 2703–2707, 2009. View at Google Scholar · View at Scopus
  33. T. Daniels, J. Zhang, I. Gutierrez et al., “Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis,” Prostate, vol. 62, no. 1, pp. 14–26, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. E. M. Tan, “Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis,” The Journal of Clinical Investigation, vol. 108, no. 10, pp. 1411–1415, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. S. B. Zeliadt, R. M. Hoffman, R. Etzioni, J. L. Gore, L. G. Kessler, and D. W. Lin, “Influence of publication of US and European prostate cancer screening trials on PSA testing practices,” Journal of the National Cancer Institute, vol. 103, no. 6, pp. 520–523, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Xie, H. J. Kim, J. G. Haw et al., “A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases,” Journal of Translational Medicine, vol. 9, article 43, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. H. Chen, S. Werner, S. Tao, I. Zornig, and H. Brenner, “Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer,” Cancer Letters, vol. 346, no. 2, pp. 178–187, 2014. View at Publisher · View at Google Scholar
  38. S. Werner, H. Chen, S. Tao, and H. Brenner, “Systematic review: serum autoantibodies in the early detection of gastric cancer,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  39. L. Weng, J. Du, Q. Zhou et al., “Identification of cyclin B1 and Sec62 as biomarkers for recurrence in patients with HBV-related hepatocellular carcinoma after surgical resection,” Molecular Cancer, vol. 11, article 39, 2012. View at Publisher · View at Google Scholar
  40. K. Aaltonen, R.-M. Amini, P. Heikkilä et al., “High cyclin B1 expression is associated with poor survival in breast cancer,” British Journal of Cancer, vol. 100, no. 7, pp. 1055–1060, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. E. M. Tan and J. Zhang, “Autoantibodies to tumor-associated antigens: reporters from the immune system,” Immunological Reviews, vol. 222, no. 1, pp. 328–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. C. R. Ritch, B. F. Morrison, G. Hruby et al., “Pathological outcome and biochemical recurrence-free survival after radical prostatectomy in African-American, Afro-Caribbean (Jamaican) and Caucasian-American men: an international comparison,” British Journal of Urology International, vol. 111, no. 4, pp. E186–E190, 2013. View at Publisher · View at Google Scholar
  43. C. A. Casiano, M. Mediavilla-Varela, and E. M. Tan, “Tumor-associated antigen arrays for the serological diagnosis of cancer,” Molecular and Cellular Proteomics, vol. 5, no. 10, pp. 1745–1759, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Wang, J. Yu, A. Sreekumar et al., “Autoantibody signatures in prostate cancer,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1224–1235, 2005. View at Publisher · View at Google Scholar
  45. L. Dai, N. Lei, M. Liu, and J. Y. Zhang, “Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC),” Experimental Hematology & Oncology, vol. 2, no. 1, article 15, 2013. View at Publisher · View at Google Scholar
  46. J. A. Koziol, J.-Y. Zhang, C. A. Casiano et al., “Recursive partitioning as an approach to selection of immune markers for tumor diagnosis,” Clinical Cancer Research, vol. 9, no. 14, pp. 5120–5126, 2003. View at Google Scholar · View at Scopus
  47. H. Ye, C. Sun, P. Ren et al., “Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer,” Oncology Letters, vol. 5, no. 2, pp. 663–668, 2013. View at Google Scholar
  48. Y. Chen, Y. Zhou, S. Qiu et al., “Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma,” Cancer Letters, vol. 289, no. 1, pp. 32–39, 2010. View at Publisher · View at Google Scholar · View at Scopus